Precision medicine is reshaping the future of healthcare by shifting the focus from one-size-fits-all treatments to therapies tailored for individual patients. As this transformation accelerates, developers must evolve to ensure that drug products are not only effective but also tailored to the specific needs of the patients they’re designed to treat.
What Tailored Formulation Development Means in Practice
In practice, tailored formulation development refers to the creation of multiple drug product profiles from a single active pharmaceutical ingredient (API), depending on the characteristics of the target population. This may include developing various delivery mechanisms, such as oral solids, inhalation powders, or subcutaneous injections, to align with factors like age, comorbidities, genetic markers, or behavioral considerations. For example, a pediatric oncology therapy may require a liquid suspension for ease of dosing, while the adult version of the same drug might be optimized for capsule delivery. In other cases, the same API may be developed as both a systemic injection and a localized implant.
Tailored formulation development also accounts for pharmacogenomic variability. Variants in metabolizing enzymes, such as CYP4501, can cause significant differences in drug metabolism between patients, leading to either underexposure or toxicity when treated with standard formulations. Scientists respond to this challenge by designing extended-release profiles, prodrugs, or formulations with absorption-modifying excipients. In parallel, lifestyle and environmental factors, such as diet, smoking, or microbiome composition, can influence drug absorption and effectiveness, all of which must be factored into drug development.
Evidence Behind the Shift to Individualized Formulation Development
Emerging real-world data and pharmacogenomic insights are driving the shift toward more nuanced formulation development. While regulatory agencies continue to approve standard formulations, post-market data often reveals suboptimal outcomes in specific subpopulations. This is well documented in cardiovascular, CNS, and respiratory therapies, where variation in pharmacokinetics or adherence frequently leads to reduced efficacy. As clinical trials increasingly stratify patients by biomarkers and phenotype, formulation development is beginning to mirror this complexity.
The Shift Toward Tailored Formulations
Rather than pursuing a one-size-fits-all strategy, modern drug product design teams are exploring how the same drug can be optimized for delivery across distinct patient subtypes. Developers of respiratory therapies may formulate the same molecule as a dry powder inhaler for ambulatory adults while creating a nebulized formulation for pediatric or elderly patients with limited inspiratory flow. Similarly, oral solid dose formulations might be re-engineered as IV infusions for oncology patients with absorption issues.
This practical evolution in formulation development requires evidence-based decisions about excipients, delivery routes, pharmacokinetics, and dosage form selection, all underpinned by stratified clinical data. As pharmacogenomic and real-world evidence become more integrated into early development, formulation scientists are better equipped to predict variability in drug response and tailor dosage forms accordingly.
Enabling Technologies for Precision Formulation Development
Tailored therapies require a flexible infrastructure for formulation development. Experic’s state-of-the-art facility supports modular workflows designed for adaptability, including:
- Dry powder inhalation and low-dose capsule filling using Harro Höfliger equipment for consistent and accurate dosing
- Spray-dried dispersions that improve the solubility and bioavailability of poorly soluble APIs
- Analytical method development and Quality by Design approaches that align formulation characteristics with clinical performance
- High potency compound containment and processing, enabling safe handling of cytotoxic or hormonal drugs
Beyond technical know-how, successful formulation development in the era of personalized medicine requires operational agility. Sponsors increasingly need CDMO partners who can develop more than one dosage form for the same API, shift between development tracks quickly, and align manufacturing with adaptive trial designs.
Experic’s expert formulation development team provides this flexibility. Whether scaling an inhaled biologic, reformulating for pediatric use, or transitioning to high potency containment, Experic’s infrastructure and team are designed to support evolving drug product needs. This enables biopharma partners to iterate based on real-time insights without compromising quality or timelines.
Addressing Future Challenges in Formulation Development
The future of formulation development encompasses biologics, gene therapies, and combination products with devices. These modalities present new formulation challenges, including ensuring the stability of fragile molecules, enabling tissue targeting, and aligning drug delivery with device design. Pharmaceutical scientists will also need to consider how digital therapeutics, AI-guided treatment regimens, and personalized diagnostics interact with drug performance.
Experic’s specialized services in inhalation powders, high potency drugs, and encapsulated delivery offer a platform for addressing these challenges. Coupled with proactive risk planning and regulatory strategy, Experic enables future-ready formulation development.
Conclusion
Formulation development is becoming one of the most critical components in delivering the promise of precision medicine. It is no longer enough to create one stable formulation and scale it. Instead, drug developers must consider how to personalize drug delivery across patient subgroups, manage variability, and respond to real-world data. With deep expertise, adaptive infrastructure, and integrated services, Experic supports clients in developing and delivering tailored drug products that perform.
Partner with Experic to advance your formulation strategy and deliver tailored therapies that make a difference.
References
- Ginsburg, G. S., & Willard, H. F. (2009). Genomic and personalized medicine: foundations and applications. Translational Research, 154(6), 277–287.